T-bet protein fights off hepatitis infections

NewsGuard 100/100 Score

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.

Hepatitis B and C viruses cause chronic infections in roughly three-quarters of infected people, putting these individuals at risk for developing liver diseases including cirrhosis and cancer. A few patients successfully eliminate infection, thanks primarily to virus-fighting immune cells called CD8+ T cells. The protective effects of CD8+ T cells depend on a cellular protein called T-bet, which is needed for the production of antiviral molecules like interferon.

Scientists in Munich, Germany, have now found that high levels of T-bet in CD8+ T cells are prevalent in individuals who successfully fight off hepatitis infections but are virtually undetectable in those who don't. The presence of T-bet went hand in hand with the production of interferon and the ability of CD8+ T cells to multiply in response to the virus. Whether boosting levels of T-bet in newly infected patients will help eliminate the virus remains to be seen.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study explores intratumoral microbiota as a novel frontier in cancer research